abraxane,paclitaxel
amgen
['sequence,(-consequence)']
sequence phase-2 study in pca : nab-p/gem and mfolfox vs nab-p/gem with significant improvements in all endpoints orr 40% vs 20%, ttp 9.3 vs 5.3, mos 13.2 vs 9.7, 12-months os rate 55% vs 35%. acceptable toxicity --&gt; great new option! 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine